Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

ClinicalTrials.gov ID: NCT05528861

Public ClinicalTrials.gov record NCT05528861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects With H-1 Antihistamine Refractory Chronic Spontaneous Urticaria

Study identification

NCT ID
NCT05528861
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Allakos Inc.
Industry
Enrollment
127 participants

Conditions and interventions

Interventions

  • Lirentelimab (AK002) Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 25, 2022
Primary completion
Dec 26, 2023
Completion
Apr 17, 2024
Last update posted
Sep 26, 2024

2022 – 2024

United States locations

U.S. sites
51
U.S. states
27
U.S. cities
47
Facility City State ZIP Site status
Allakos Investigational Site 227-024 Birmingham Alabama 35209
Allakos Investigational Site 227-068 Cullman Alabama 35058
Allakos Investigational Site 227-014 Phoenix Arizona 85021
Allakos Investigational Site 227-023 Scottsdale Arizona 85251
Allakos Investigational Site 227-058 Bakersfield California 93301
Allakos Investigational Site 227-026 Los Angeles California 90025
Allakos Investigational Site 227-009 Los Angeles California 90045
Allakos Investigational Site 227-011 Mission Viejo California 92691
Allakos Investigational Site 227-021 Santa Monica California 90404
Allakos Investigational Site 227-031 Upland California 91786
Allakos Investigational Site 227-006 Colorado Springs Colorado 80907
Allakos Investigational Site 227-036 Jacksonville Florida 32256
Allakos Investigational Site 227-062 Miami Florida 33135
Allakos Investigational Site 227-041 Sarasota Florida 34239
Allakos Investigational Site 227-067 Tampa Florida 33607
Allakos Investigational Site 227-005 Tampa Florida 33613
Allakos Investigational Site 227-018 Columbus Georgia 31904
Allakos Investigational Site 227-045 Boise Idaho 83706
Allakos Investigational Site 227-045 Normal Illinois 61761
Allakos Investigational Site 227-057 River Forest Illinois 60305
Allakos Investigational Site 227-074 Plainfield Indiana 46168
Allakos Investigational Site 227-047 Overland Park Kansas 66211
Allakos Investigational Site 227-051 Lexington Kentucky 40509
Allakos Investigational Site 227-019 Baltimore Maryland 21224
Allakos Investigational Site 227-012 Towson Maryland 21204
Allakos Investigational Site 227-063 White Marsh Maryland 21162
Allakos Investigational Site 227-016 Boston Massachusetts 02111
Allakos Investigational Site 227-034 Ann Arbor Michigan 48106
Allakos Investigational Site 227-032 Detroit Michigan 48202
Allakos Investigational Site 227-070 Farmington Hills Michigan 48346
Allakos Investigational Site 227-073 Dilworth Minnesota 56529
Allakos Investigational Site 227-052 Rochester Minnesota 55905
Allakos Investigational Site 227-008 St Louis Missouri 63141
Allakos Investigational Site 227-059 Missoula Montana 59808
Allakos Investigational Site 227-022 Brooklyn New York 11203
Allakos Investigational Site 227-007 Great Neck New York 11021
Allakos Investigational Site 227-002 Asheville North Carolina 28801
Allakos Investigational Site 227-013 Cincinnati Ohio 45229
Allakos Investigational Site 227-029 Cincinnati Ohio 45236
Allakos Investigational Site 227-043 Columbus Ohio 43235
Allakos Investigational Site 227-064 Toledo Ohio 43617
Allakos Investigational Site 227-060 Oklahoma City Oklahoma 73170
Allakos Investigational Site 227-027 Portland Oregon 97223
Allakos Investigational Site 227-028 Hershey Pennsylvania 17033
Allakos Investigational Site 227-040 Philadelphia Pennsylvania 19103
Allakos Investigational Site 227-066 North Charleston South Carolina 29420
Allakos Investigational Site 227-055 Austin Texas 78759
Allakos Investigational Site 227-049 El Paso Texas 79903
Allakos Investigational Site 227-039 Murray Utah 84107
Allakos Investigational Site 227-071 Murray Utah 84107
Allakos Investigational Site 227-033 Greenfield Wisconsin 53228

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05528861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 26, 2024 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05528861 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →